• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OTUD7B和NIK在非小细胞肺癌中的表达:与临床病理特征的关联及预后意义

OTUD7B and NIK expression in non-small cell lung cancer: Association with clinicopathological features and prognostic implications.

作者信息

Zhang Boxiang, Wang Huangzhen, Yang Litao, Zhang Yiwen, Wang Peili, Huang Guanghong, Zheng Jie, Ren Hong, Qin Sida

机构信息

Department Two of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China.

Clinical Research Center,the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China.

出版信息

Pathol Res Pract. 2016 Oct;212(10):893-898. doi: 10.1016/j.prp.2016.07.011. Epub 2016 Jul 25.

DOI:10.1016/j.prp.2016.07.011
PMID:27499151
Abstract

PURPOSE

To investigate the correlation among OTUD7B and NIK expression and the clinicopathological characteristics in NSCLC patients.

METHODS

One hundred and twenty patients were involved in this study. We detected OTUD7B and NIK expression by immunohistochemistry and analyzed their correlation with clinicopathological data.

RESULTS

The expression of OTUD7B and NIK were negatively correlated in NSCLC tumor samples (r=-0.421, P<0.001). The higher expression of OTUD7B was associated with smaller tumor size(P=0.018), less lymph node metastasis (P=0.012) and earlier TNM stage(P=0.039), while the higher expression of NIK was only related to more lymph node metastasis(P=0.031) and later TNM stage(P=0.011). MMP-9 was negatively correlated with OTUD7B and positively correlated with NIK. In addition, the high expression of OTUD7B was associated with good prognosis of NSCLC patients (log-rank=6.714, P=0.0096), and a high OTUD7B/low NIK index can predict an even better prognosis (log-rank=11.794, P=0.0006). Moreover, the multivariate Cox regression analysis showed that OTUD7B rather than NIK is an independent marker of overall survival in NSCLC patients(HR=1.602, 95% CI 1.009-2.544, P=0.046).

CONCLUSIONS

OTUD7B and NIK may play important roles in the development of lung cancer. The combination of OTUD7B and NIK expression may be a good index for predicting the prognosis of NSCLC.

摘要

目的

探讨OTUD7B和NIK表达与非小细胞肺癌(NSCLC)患者临床病理特征之间的相关性。

方法

本研究纳入120例患者。我们通过免疫组织化学检测OTUD7B和NIK表达,并分析它们与临床病理数据的相关性。

结果

NSCLC肿瘤样本中OTUD7B和NIK的表达呈负相关(r = -0.421,P < 0.001)。OTUD7B表达越高,与肿瘤体积越小(P = 0.018)、淋巴结转移越少(P = 0.012)及TNM分期越早(P = 0.039)相关,而NIK表达越高仅与更多的淋巴结转移(P = 0.031)和更晚的TNM分期(P = 0.011)相关。基质金属蛋白酶-9(MMP-9)与OTUD7B呈负相关,与NIK呈正相关。此外,OTUD7B高表达与NSCLC患者的良好预后相关(对数秩检验= 6.714,P = 0.0096),高OTUD7B/低NIK指数可预测更好的预后(对数秩检验= 11.794,P = 0.0006)。而且,多因素Cox回归分析显示,OTUD7B而非NIK是NSCLC患者总生存的独立标志物(风险比= 1.602,95%可信区间1.009 - 2.544,P = 0.046)。

结论

OTUD7B和NIK可能在肺癌发生发展中起重要作用。OTUD7B和NIK表达的联合可能是预测NSCLC预后的良好指标。

相似文献

1
OTUD7B and NIK expression in non-small cell lung cancer: Association with clinicopathological features and prognostic implications.OTUD7B和NIK在非小细胞肺癌中的表达:与临床病理特征的关联及预后意义
Pathol Res Pract. 2016 Oct;212(10):893-898. doi: 10.1016/j.prp.2016.07.011. Epub 2016 Jul 25.
2
Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.肝脏激酶B1和Beclin1表达降低与非小细胞肺癌患者的不良生存相关。
Oncol Rep. 2014 Nov;32(5):1931-8. doi: 10.3892/or.2014.3432. Epub 2014 Aug 21.
3
Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.非小细胞肺癌中Gankyrin蛋白表达的临床病理特征及预后意义
Pathol Res Pract. 2015 Dec;211(12):939-47. doi: 10.1016/j.prp.2015.09.010. Epub 2015 Sep 10.
4
[Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].[非小细胞肺癌(NSCLC)患者中叉头框M1(FOXM1)表达与临床病理特征及预后的相关性]
Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):426-30.
5
High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.MAGE - A9在非小细胞肺癌的肿瘤细胞和基质细胞中的高表达与患者的不良生存相关。
Int J Clin Exp Pathol. 2015 Jan 1;8(1):541-50. eCollection 2015.
6
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.细胞周期蛋白依赖性激酶5(CDK5)在非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)中表达的免疫组织化学研究:一种可能的预后生物标志物。
World J Surg Oncol. 2016 Feb 9;14(1):34. doi: 10.1186/s12957-016-0787-7.
7
Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer.氨肽酶N/CD13在非小细胞肺癌中的表达及临床意义
J Cancer Res Ther. 2015 Jan-Mar;11(1):223-8. doi: 10.4103/0973-1482.138007.
8
High TBX2 expression predicts poor prognosis in non-small cell lung cancer.TBX2 高表达预示非小细胞肺癌预后不良。
Neoplasma. 2014;61(4):476-80.
9
Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.血管生成素-2在非小细胞肺癌患者中的预后价值:一项荟萃分析。
World J Surg Oncol. 2016 Sep 2;14(1):237. doi: 10.1186/s12957-016-0992-4.
10
Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.下调的微小RNA 148b表达作为预测生物标志物及其与非小细胞肺癌患者临床病理特征相关的预后意义
Diagn Pathol. 2015 Sep 17;10:164. doi: 10.1186/s13000-015-0393-y.

引用本文的文献

1
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.OTUD7B表达降低通过非经典核因子κB信号通路与外周T细胞淋巴瘤预后不良相关。
Int J Hematol. 2025 Feb;121(2):194-205. doi: 10.1007/s12185-024-03877-y. Epub 2024 Dec 5.
2
OTUD7B knockdown inhibits the proliferation and stemness of breast cancer cells by destabilizing FOXM1.OTUD7B基因敲低通过使FOXM1蛋白不稳定来抑制乳腺癌细胞的增殖和干性。
Oncol Lett. 2024 Jan 16;27(3):102. doi: 10.3892/ol.2024.14235. eCollection 2024 Mar.
3
AtomNet-Aided OTUD7B Inhibitor Discovery and Validation.
AtomNet辅助的OTUD7B抑制剂的发现与验证
Cancers (Basel). 2023 Jan 14;15(2):517. doi: 10.3390/cancers15020517.
4
Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma.去泛素化酶OTUD7B是弥漫性大B细胞淋巴瘤中一种潜在的预后生物标志物。
J Cancer. 2022 Jan 4;13(3):998-1004. doi: 10.7150/jca.65835. eCollection 2022.
5
Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.用小分子对NF-κB诱导激酶(NIK)进行药理学抑制以治疗人类疾病。
RSC Med Chem. 2021 Jan 22;12(4):552-565. doi: 10.1039/d0md00361a. eCollection 2021 Apr 28.
6
Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway.长链非编码 RNA 00976 通过海绵吸附 miR-137 促进 OTUD7B 进而促进胰腺癌进展,涉及 EGFR/MAPK 通路。
J Exp Clin Cancer Res. 2019 Nov 20;38(1):470. doi: 10.1186/s13046-019-1388-4.
7
Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.OTUD7B(塞尚蛋白)的上调通过AKT/血管内皮生长因子途径促进肺鳞癌和腺癌的肿瘤进展。
Front Oncol. 2019 Sep 11;9:862. doi: 10.3389/fonc.2019.00862. eCollection 2019.
8
Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-α Subunit Abundance.E3 连接酶和去泛素化酶在 HIF-α亚基丰度调控中的作用。
Cells. 2019 Jun 15;8(6):598. doi: 10.3390/cells8060598.
9
Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?去泛素化酶作为癌症生物标志物:新的治疗机会?
BMB Rep. 2019 Mar;52(3):181-189. doi: 10.5483/BMBRep.2019.52.3.048.